Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 1 (2004), Issue 3 (December)

1. Strategies to overcome resistance to targeted protein kinase inhibitors.
   Nat Rev Drug Discov, 3(12): 1001-10. [Abstract] [Full-text]
2. Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein.
   Blood, 104(13): 4219-25. [Abstract] [Full-text]
3. Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia.
   Blood, 104(13): 4245-51. [Abstract] [Full-text]
4. Kit as a human oncogenic tyrosine kinase.
   Cell Mol Life Sci, 61(23): 2924-31. [Abstract] [Full-text]
5. Oncogenic derivatives of platelet-derived growth factor receptors.
   Cell Mol Life Sci, 61(23): 2912-23. [Abstract] [Full-text]
6. A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer.
   Prostate, 62(2): 115-22. [Abstract] [Full-text]
7. Growth factor receptor expression in orbital lymphangioma: possible therapeutic implications.
   Orbit, 23(4): 263-9. [Abstract] [Full-text]
8. Differential protein expression profile in gastrointestinal stromal tumors.
   Amino Acids, 27(3): 335-7. [Abstract] [Full-text]
9. Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemia.
   Leukemia, 19(1): 39-43. [Abstract] [Full-text]
10. KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32).
    Leukemia, 19(1): 27-30. [Abstract] [Full-text]
11. BCR/ABL activates Rap1 and B-Raf to stimulate the MEK/Erk signaling pathway in hematopoietic cells.
    Biochem Biophys Res Commun, 326(3): 645-51. [Abstract] [Full-text]
12. In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy.
    Int J Cancer, 113(5): 849-56. [Abstract] [Full-text]
13. Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens.
    Ann Oncol, 16(1): 7-15. [Abstract] [Full-text]
14. Expression of c-kit in uterine carcinosarcoma.
    Gynecol Oncol, 96(1): 210-5. [Abstract] [Full-text]
15. Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma.
    Br J Cancer, 91(12): 2048-55. [Abstract] [Full-text]
16. Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations.
    Proc Natl Acad Sci U S A, 101(50): 17456-61. [Abstract] [Full-text]
17. Two different pathways link G-protein-coupled receptors with tyrosine kinases for the modulation of growth and survival in human hematopoietic progenitor cells.
    Cell Signal, 17(4): 447-59. [Abstract] [Full-text]
18. Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines.
    Lung Cancer, 47(1): 31-9. [Abstract] [Full-text]
19. Interferon-gamma-dependent in vitro model for the putative keratin 17 autoimmune loop in psoriasis: exploration of pharmaco- and gene-therapeutic effects.
    Skin Pharmacol Physiol, 18(1): 42-54. [Abstract] [Full-text]
20. Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors.
    Ann Pharmacother, 39(1): 162-4. [Abstract] [Full-text]
21. Every case of essential thrombocythemia should be tested for the Philadelphia chromosome.
    Am J Hematol, 78(1): 71-3. [Abstract] [Full-text]
22. A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase.
    J Biol Chem, 279(53): 55827-32. [Abstract] [Full-text]
23. Chemical proteomic analysis reveals alternative modes of action for pyrido[2,3-d]pyrimidine kinase inhibitors.
    Mol Cell Proteomics, 3(12): 1181-93. [Abstract] [Full-text]
24. Treatment of cockroach allergen asthma model with imatinib attenuates airway responses.
    Am J Respir Crit Care Med, 171(1): 35-9. [Abstract] [Full-text]
25. New approaches in the treatment of myelofibrosis.
    Cancer, 103(1): 32-43. [Abstract] [Full-text]
26. Overproduction of BCR-ABL induces apoptosis in imatinib mesylate-resistant cell lines.
    Cancer, 103(1): 102-10. [Abstract] [Full-text]
27. In vitro drug resistance to imatinib and mutation of ABL gene in childhood Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.
    Leuk Lymphoma, 46(2): 273-6. [Abstract] [Full-text]
28. Mastocytosis: pathology, genetics, and current options for therapy.
    Leuk Lymphoma, 46(1): 35-48. [Abstract] [Full-text]
29. Rapid reversion of Loeffler's endocarditis by imatinib in early stage clonal hypereosinophilic syndrome.
    Leuk Lymphoma, 45(12): 2503-7. [Abstract] [Full-text]
30. Imatinib-responsive hypereosinophilia in a patient with B cell ALL.
    Leuk Lymphoma, 45(12): 2497-501. [Abstract] [Full-text]
31. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors.
    J Clin Oncol, 23(1): 49-57. [Abstract] [Full-text]

© 2004-2008 Glivec Research Today. All Rights Reserved.